XSpray Pharma AB has appointed Michael af Winklerfelt as acting CFO, beginning, February 8, 2024. The company?s current CFO Kerstin Hasselgren leaves the role at her own request and will transition to another internal role as Senior Advisor and Head of IR. Michael af Winklerfelt has extensive experience from similar roles at listed life science companies, most recently at Prostatype Genomics.

He also has extensive experience from international assignments and has an MSc from Stockholm School of Economics and an MBA from Emory University. Michael af Winklerfelt will replace Kerstin Hasselgren who has been the company?s CFO since 2019 and who now leaves the role at her own request due to personal reasons. Kerstin Hasselgren will remain in the company as Head of IR and Senior Advisor to management.

Michael af Winklerfelt will until further notice be acting CFO and will begin in his role on February 8, 2024.